Oragenics Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer
Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing "Spike Protein"
By David Bautz, PhD NASDAQ:BCLI READ THE FULL OGEN RESEARCH REPORT Business Update Developing Vaccine Against SARS-CoV-2 On May 4, 2020, Oragenics, Inc. (OGEN) announced the acquisition of Noachis Terra Inc., which is developing TerraCoV2, a vaccine candidate against SARS-CoV-2 (the virus that causes COVID-19) that is licensed from the National Institute of Allergy and Infectious Diseases
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Oragenics Announces New Member of the Board of Directors
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Enrollment Complete for Phase 2 Trial of AGO13 in Oral Mucositis Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). AG013 is an oral mouth rinse composed of a recombinant Lactococcus lactis strain that
On May 20, 2019, Oragenics, Inc. (OGEN) announced that the 80th patient has been enrolled in the company’s ongoing Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). In addition, the World Health Organization provided the company with the generic name dapatifagene navolactibac for AG013. The trefoil factor family (TFF) is a family of three different peptides secreted by epithelial cells of the gastrointestinal tract in response to injury (Hoffman, 2004).
Anyone researching Oragenics, Inc. (NYSEMKT:OGEN) might want to consider the historical volatility of the share price...
Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a SARS-CoV-2 (COVID 19) Vaccine Candidate
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Topline Data for Phase 2 Trial of AGO13 in Oral Mucositis in Early 2Q20 Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). AG013 is an oral mouth rinse composed of a recombinant Lactococcus lactis strain
By David Bautz, PhD NYSE:OGEN READ THE FULL OGEN RESEARCH REPORT Business Update Poster on Phase 2 Trial of AG013 Presented at ESMO 2019 On September 30, 2019, Oragenics, Inc. (NYSE:OGEN) announced the presentation of a poster discussing the ongoing Phase 2 clinical trial of AG013 in severe oral mucositis (SOM) at the European Society for Medical Oncology (ESMO) Congress 2019. The company also